Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases

Inclusion Criteria: * Systemic rheumatic disease (Systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies including antisynthetasis syndromes (IIM), mixed connective tissue disease (MCTD) or Sjøgrens disease (SjD)) classifiable by disease-specific classification criteria * Diagnosed interstitial lung disease (ILD) on high resolution computed tomography (HRCT) ≥ 1 year prior to randomization, not explained by other diseases or exposures * On stable standard of care treatment 6 months prior to randomization * Participants must be able to understand and follow trial procedures including completion of questionnaires regarding Patient Reported Outcome measures * Participants must have access to the internet, and experience in using smartphones or other electronic devices with internet access * Signed informed consent form Exclusion Criteria: * Severe heart failure with ejection fraction (EF) \< 30% * Chronic renal failure G4 or more (defined by KDIGO) with glomerular filtration rate (eGFR) \< 30 mL/min using Cockroft-Gault formula. * End stage lung disease with forced vital capacity (FVC) \< 50% and/or diffusion capacity for carbon monoxide (DLCO) \< 40% or coexisting severe other lung diseases (e.g. chronic obstructive pulmonary disease, emphysema) * Airway obstruction (pre-bronchodilator FEV1/FVC \< 0.7) (FEV1 is defined as forced expiratory volume in 1 sec) * In the opinion of the investigator, other clinically significant pulmonary abnormalities * Significant pulmonary hypertension defined by the following: Previous clinical or echocardiographic evidence of significant right heart failure OR history of right heart catheterization showing a cardiac index \</= 2 L/min/m2 OR pulmonary hypertension requiring therapy with epoprostenol/treprostinil * Active treatment for cancer or non-curable cancer * Relative contraindications to performing spirometry, as specified in ATS/ERS guidelines. * Ongoing Prednisolone ≥ 20 mg/day at inclusion * Unable to speak, write and read Norwegian, German or Romanian in the respective country of inclusion. * Unable to perform good quality measurements of FVC on the home-device comparable to results on an in-hospital device, after training. * Pregnancy or planned pregnancy